Inhaled Nitric Oxide Should Be Used Over Vasopressin for Acute Pulmonary Hypertension
In acute pulmonary hypertension, inhaled nitric oxide (iNO) is the preferred first-line pulmonary vasodilator, while vasopressin serves as a complementary systemic vasopressor—these agents address different aspects of hemodynamic management and are not interchangeable.
The Fundamental Distinction
These two medications target entirely different physiologic problems and should not be viewed as alternatives to one another:
- Inhaled nitric oxide is a selective pulmonary vasodilator that reduces pulmonary vascular resistance (PVR) and unloads the failing right ventricle 1
- Vasopressin is a systemic vasopressor used to maintain systemic vascular resistance (SVR) above PVR, preventing right ventricular ischemia 1
The critical management principle in acute PH is maintaining SVR > PVR to preserve right ventricular coronary perfusion, which occurs during both systole and diastole 1. When systolic pulmonary arterial pressure exceeds systolic systemic arterial pressure, right ventricular ischemia results 1.
Inhaled Nitric Oxide as First-Line Pulmonary Vasodilator
iNO is routinely employed at 20 parts per million in the ICU for hypotensive PH patients 1. The evidence supporting this approach includes:
Key Advantages
- Selective pulmonary vasodilation without detrimental effects on SVR 1
- Short half-life and rapid onset allowing precise titration 1
- Improves oxygenation through enhanced ventilation-perfusion matching 1
- Unloads the acutely failing right ventricle 1
- Particularly effective post-coronary bypass surgery or valve replacement 1
Dosing and Administration
Start at 5-10 ppm for ARDS-related PH 2, or 20 ppm for acute critical illness in PAH 1. Doses >20 ppm rarely provide additional benefit 3. The FDA-approved indication is for neonatal hypoxic respiratory failure, but off-label use in adults with acute PH is widespread in expert centers 4.
Important Caveats
- Rebound pulmonary hypertension can occur upon withdrawal, particularly without replacement pulmonary vasodilator 1, 3
- Wean slowly to <1-5 ppm before discontinuation, or start a phosphodiesterase-5 inhibitor (sildenafil) as replacement therapy 1, 3
- Monitor for methemoglobinemia (though rare at standard doses) 4
- Significant cost consideration 1
Vasopressin's Complementary Role
Vasopressin is used to offset the potential drop in SVR from inotropes (dobutamine, milrinone) while maintaining the SVR > PVR gradient 1. This is particularly important in:
- Septic PH patients with vasopressin deficiency 1
- Liver disease-associated PH with vasopressin deficiency 1
- Any hypotensive PH patient requiring inotropic support 1
The strategy is to use replacement-dose vasopressin alongside inotropes that have neutral or beneficial effects on PVR (dobutamine, milrinone, epinephrine) 1.
Practical Management Algorithm
For Acute PH Crisis:
Immediate hemodynamic assessment: Central line with CVP and mixed venous saturation monitoring 1
Maintain SVR > PVR:
Reduce PVR with iNO:
Optimize ventilation to avoid increasing PVR:
Plan for iNO weaning:
Evidence Limitations and Controversies
While iNO consistently improves oxygenation and hemodynamics in acute PH, mortality benefit has not been demonstrated in adult populations 4. A large ARDS trial showed acute oxygenation improvements but no effect on ventilator-free days or survival 4. However, the absence of mortality benefit does not negate its role as a bridge therapy for acute RV failure or as a tool to facilitate separation from mechanical support.
The 2016 ICM expert opinion notes that inhaled selective pulmonary vasodilators "have not yet been rigorously tested for this specific indication in ARDS" but acknowledges they may improve RV function 2. The 2014 Circulation Research guideline is more definitive, stating iNO is "routinely employed" in hypotensive PH patients in the ICU 1.
Bottom Line
Use iNO (20 ppm) as your first-line pulmonary vasodilator for acute PH with RV failure, and use replacement-dose vasopressin to maintain systemic pressure—they work synergistically, not as alternatives. This combination addresses both sides of the hemodynamic equation: reducing RV afterload while preserving RV coronary perfusion pressure.